Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Fixed Dose Ivermectin 18 mg vs Reference
NCT03173742Phase 1Completed
- Sponsor
- Insud Pharma
- Start
- Mar 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of CHILD-IVITAB in helminthiasis (6 arms), sponsored by Insud Pharma. Primary endpoints: Area Under the Curve from time 0 to last measurable concentration and Maximum Plasma Concentration. Started Mar 2016; status: completed.
02
Drugs
CHILD-IVITAB
03
Conditions
helminthiasis
Beyond the preview
Go deeper on NCT03173742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03173742.